痰热清注射液联合胸腺肽α1治疗慢性阻塞性肺疾病急性加重期临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563

基金项目:

金华市科学技术公益类项目(2018-4-090)


Clinical Study on Tanreqing Injection Combined with Thymosin α1 for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察痰热清注射液联合胸腺肽α1 治疗慢性阻塞性肺疾病急性加重期(AECOPD) 患者的临床疗效。方法:选择92 例AECOPD 患者,按随机数字表法分为对照组与观察组各46 例。对照组给予常规治疗,观察组在常规治疗的基础上加用痰热清注射液联合胸腺肽α1 治疗。比较2 组临床疗效、免疫功能、炎症标志物、肺功能、动脉血气分析指标及不良反应发生情况。结果:治疗后,观察组总有效率93.48%,高于对照组78.26% (P<0.05)。与同组治疗前比较,治疗后2 组降钙素原(PCT)、C-反应蛋白(CRP)、白细胞计数(WBC)、肿瘤坏死因子-α (TNF-α)、CD8+、二氧化碳分压(PaCO2) 水平均降低(P<0.05),CD3+、CD4+、CD4+/CD8+、动脉血氧分压(PaO2)、用力肺活量(FVC)、第1 秒用力呼气容积(FEV1)、FEV1/FVC水平均升高(P<0.05);与对照组治疗后比较,观察组治疗后PCT、CRP、TNF-α、WBC、CD8+、PaCO2 水平均较低(P<0.05),CD3+、CD4+、CD4+/CD8+、PaO2、FEV1、FVC、FEV1/FVC 水平均较高(P<0.05)。2 组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采用痰热清注射液联合胸腺肽α1 治疗AECOPD 患者能有效减轻患者炎症反应,提高免疫功能,改善动脉血气指标及肺功能。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the therapy of Tanreqing injection combined with thymosin α1 on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Methods: A total of 92 patients with AECOPD were selected and divided into the control group and the observation group according to the random number table method, with 46 cases in each group. The control group was given routine treatment, and the observation group was additionally given Tanreqing injection combined with thymosin α1 based on the routine treatment. The clinical effects, immune function,inflammatory markers,the lung function,indexes of arterial blood gas analysis and adverse reactions in the two groups were compared. Results: After treatment, the total effective rate was 93.48% in the observation group, higher than that of 78.26% in the control group(P<0.05). After treatment,the levels of procalcitonin(PCT),C-reactive protein (CRP),white blood count(WBC),tumor necrosis factor-α(TNF-α),CD8+,and partial pressure of carbon dioxide(PaCO2) in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of CD3+,CD4+,CD4+/ CD8 + , arterial partial pressure of oxygen(PaO2), forced vital capacity(FVC), forced expiratory volume in the one second (FEV1), and FEV1/FVC were increased(P<0.05); the levels of PCT, CRP, TNF- α, WBC, CD8 + and PaCO2 in the observation group were lower than those in the control group(P<0.05),and the levels of CD3+,CD4+,CD4+/CD8+,PaO2, FEV1, FVC and FEV1/FVC were higher(P<0.05). There was no significant difference being found in the comparison of incidence of adverse reactions between the two groups(P>0.05). Conclusion:The therapy of Tanreqing injection combined with thymosin α1 for patients with AECOPD can effectively reduce the inflammatory responses and improve the immune function,index of arterial blood gas and the lung function.

    参考文献
    相似文献
    引证文献
引用本文

范红娟,张向明,汪根良.痰热清注射液联合胸腺肽α1治疗慢性阻塞性肺疾病急性加重期临床研究[J].新中医,2021,53(23):92-95

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-12-10
  • 出版日期: